Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Niraparib (Primary)
- Indications Soft tissue sarcoma; Uterine cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2023 Planned End Date changed from 1 Aug 2024 to 1 Aug 2026.
- 15 Aug 2023 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2026.